Quick Answer
Barinthus Biotherapeutics plc. reported Research And Development Expense of $25.56 million for the year ending 2025.
- Barinthus Biotherapeutics plc. showed a decrease of -39.5% in Research And Development Expense from 2024 to 2025.
- This data is from Barinthus Biotherapeutics plc.'s annual report (Form 10-K), filed with the SEC on March 13, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: $4.24 million | Q2 2020: $3.88 million | Q3 2020: $3.70 million | Q1 2021: $4.61 million | Q2 2021: $4.51 million | Q3 2021: $4.37 million | Q1 2022: $10.70 million | Q2 2022: $9.72 million | Q3 2022: $9.74 million | Q1 2023: $9.81 million | Q2 2023: $13.54 million | Q3 2023: $15.14 million | Q1 2024: $11.13 million | Q2 2024: $11.66 million | Q3 2024: $11.14 million | Q1 2025: $8.29 million | Q2 2025: $7.95 million | Q3 2025: $5.39 million.
- Over the full 6 years of available data (2020 to 2025), Barinthus Biotherapeutics plc.'s Research And Development Expense has grown by 77.7%.
- Historical annual values: Fiscal year 2025: $25.56 million | Fiscal year 2024: $42.24 million | Fiscal year 2023: $44.87 million | Fiscal year 2022: $42.35 million | Fiscal year 2021: $20.37 million | Fiscal year 2020: $14.39 million.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: